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Abstract
Background: Adherence to guidelines for the treatment of hospitalized elderly patients with community-acquired
pneumonia (CAP) has been associated with improved clinical outcomes. This study evaluated the cost-effectiveness
of adherence to guidelines for the treatment of CAP in an elderly hospitalized patient cohort.
Methods: Data from an international, multicenter observational study for patients age 65 years or older hospitalized
with CAP from 2001 to 2007 were used to estimate transition probabilities for a multi-state Markov model
traversing multiple health states during hospitalization for CAP. Empiric antibiotic therapy was classified as adherent,
over-treated, and under-treated according to 2007 Infectious Disease Society of America/American Thoracic Society
IDSA/ATS guidelines. Utilities were estimated from an expert panel of active clinicians. Costs were estimated from a
tertiary referral hospital and adjusted for inflation to 2013 US dollars. Costs, utilities, and transition probabilities were
all modeled using probability distributions to handle their inherit uncertainty. Cost-effectiveness analysis was based
on the first 14 days of hospitalization. Patients admitted to the intensive care unit (ICU) were analyzed separately
from those admitted to the ward. Sensitivity analyses with regards to time frame (out to 30 days hospitalization),
cost estimates, and willingness to pay values were performed.
Results: The model parameters were estimated using data from 1635 patients (1438 admitted to the ward and 197
admitted to the ICU). For the ward model, adherence to antibiotic guidelines was the dominant strategy and associated
with lower costs (−$1379 and −$799) and improved quality of life compared to over- and under-treatment. In the ICU
model, however, adherence to guidelines was associated with greater costs (+$13,854 and + $3461 vs. over- and under-
treatment, respectively) and lower quality of life. Acceptance rates across the willingness to pay ranges evaluated were
42–48 % for guideline adherence on the ward and 61–64 % for over-treatment on the ICU. Results were robust over
sensitivity analyses concerning cost and utility estimates.
Conclusions: While adherence to antibiotic guidelines was the most cost-effective strategy for elderly patients
hospitalized with CAP and admitted to the ward, in the ICU over-treatment of patients relative to the guidelines was the
most cost-effective strategy.
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Background
Pneumonia is one of the leading causes of death in the
United States, and a leading cause of hospitalizations is
community-acquired pneumonia (CAP) [1, 2]. Hospitali-
zations are increasing for infectious disease-related
problems in the elderly, particularly for pneumonia [3,
4]. For these reasons, the treatment of elderly patients
hospitalized with CAP is a major component of health
care spending in America and an important public
health issue.
Clinical practice guidelines have been developed to
guide antibiotic choice in hospitalized CAP by the Infec-
tious Diseases Society of America and the American
Thoracic Society (IDSA/ATS) [5]. Clinical practice
guidelines are becoming more common across multiple
medical disciplines. They are generally formed from
evidence-based reviews by experts in their field and pro-
mulgated by national or international professional soci-
eties in an effort to disseminate best practices and
improve patient outcomes. There is evidence to suggest
that adherence to guidelines may improve mortality and
time to clinical stability (TCS) in CAP [6, 7]. Adherence
to the 2007 IDSA/ATS guidelines improves mortality,
length of stay (LOS), and TCS in elderly patients hospi-
talized with CAP [8].
Cost effectiveness research will be a critical part of
healthcare spending and intervention evaluation in the
future of American healthcare. It is incumbent upon
practitioners to not only deliver medical care with good
clinical outcomes, but also to consider those interven-
tions that most efficiently use scarce healthcare re-
sources. The cost effectiveness of practice guideline
adherence has been evaluated and found to be cost-
effective in a variety of medical conditions [9–12]. The
cost effectiveness of adherence to antibiotic guidelines in
CAP has only been evaluated in a limited number of
studies [6, 13, 14]. This study was performed in an effort
to determine the cost-effectiveness of adherence to
IDSA/ATS antibiotic guidelines for the treatment of
CAP in hospitalized elderly patients (age ≥ 65).
Methods
Data source
This study is a retrospective study utilizing patient and
outcome data from the Community Acquired Pneumo-
nia Organization (CAPO) International Study Cohort,
which is an international, multicenter observational
study of patients hospitalized with CAP [15]. Data were
abstracted from the database from June 1, 2001 to Janu-
ary 1, 2007 for all patients age 65 years or older and in-
cluded data from 43 centers in 12 countries including
North America, South America, Europe, Africa, and
Southeast Asia (see Arnold et al. [8] for details concern-
ing the patient cohort used in this study and the
‘Availability of Data and Materials’ section). The study
was approved by the Human Subject Protection Pro-
gram Institutional Review Board at the University of
Louisville. Additional approval was obtained from the
local internal review board for each participating hos-
pital. Patient consent was waived due to the retrospect-
ive and observational study design. The initial antibiotic
regimen for each patient was evaluated and categorized
as adherent, over-treated, or under-treated according to
the 2007 IDSA/ATS guidelines as previously described
[5, 8]. Patients were stratified into ICU or ward admis-
sion status based on their initial admission orders. A pa-
tient was considered clinically stable on the day they
were switched to oral antibiotics from intravenous anti-
biotics; ATS criteria for switching to oral therapy were
used [16]. A small number of patients were admitted
with oral antibiotics as their initial therapy; these pa-
tients were considered clinically stable upon admission.
Baseline characteristics of the cohorts of interest were
compared using chi-square or Fisher exact for categor-
ical data, as appropriate, medians were compared with
Kruska-Wallis test, and probabilities compared using
Gray’s test for difference between cumulative incidence
curves [17].
Markov model
A 14-cycle Markov model was constructed modeling the
four possible states in which a patient could exist during
the 14 day observation period (Fig. 1). Each cycle is a
24 h period during the patient’s hospitalization. Patients
admitted to the hospital (state 1) remained in this initial
state until they either reached clinical stability (state 2),
were discharged (state 3), or died in the hospital (state
4). Patients who reached clinical stability remained in
that state until they were subsequently discharged. Pa-
tients initially admitted to the ICU were assumed to re-
main in the ICU until they died or reached clinically
stability, after which they were transferred to the ward.
Prior to reaching clinically stability patients were on
intravenous medication, after which they were placed on
oral medications.
Conditional transition probabilities for each possible
transition from state i to state j (see Fig. 1) at time
t ∈ [1, 14] were estimated based on the cause-specific
transition hazards αij (t). Non-parametric estimates of
the transition hazards were based on the number of in-
dividuals making the i → j transition at time t divided
by the number of individuals in state i just prior to time
t (i.e., the number ‘at-risk’ of making the i → j transi-
tion). Non-parametric estimates of the conditional tran-
sition probabilities were then obtained using the Aalen-
Johansen estimator with the R package msSurv [18, 19].
Parametric estimates were obtained by first fitting time-
dependent Cox regression models to each of the possible
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transition hazards outlined in Fig. 1. These estimates of
the transition hazards were then used to obtain esti-
mated transition probabilities for an individual with a
given covariate profile using the R package mstate [20].
The covariates (in addition to adherence to antibiotic
guidelines) used in the parametric models were disease
severity (pneumonia severity index (PSI) risk class ≥4 vs.
<4), presence of multilobar pneumonia, pleural effusion,
altered mental status, tachypnea (respiratory rate > 30
breaths/min), hypotension (systolic blood pressure <
90 mm Hg), receipt of antimicrobials within 8 h of ad-
mission, pneumococcal vaccination, blood cultures ob-
tained within 24 h of admission, and whether oxygen
assessment was done [21]. All covariates were dichotom-
ous, and the parametric transition probabilities were
based on the most frequently occurring value for each
covariate. Daily transition probabilities (the probability
of making an i → j transition from time t to t + 1) were
obtained from both parametric and non-parametric esti-
mates and compared to ensure validity. The daily transi-
tion probabilities from the parametric multi-state model
were modeled as continuous beta distributions in the
Markov model based on the estimates and standard er-
rors from the parametric model.
The antibiotic decision making was modeled using
three comparators: Adherent, Over-treated, and Under-
treated [8]. The multi-state Markov process followed the
decision making nodes. ICU admissions and ward ad-
missions were analyzed in two separate models. Cost-
effectiveness analyses, probabilistic sensitivity analyses,
and a Monte Carlo microsimulation with 10,000 patients
were performed. For conciseness only results from tran-
sition probability estimates based on the parametric
models are reported, however substantive conclusions
based on the non-parametric estimates did not differ.
“Adherent” was considered the base case comparator,
against which the over- and under-treated groups were
compared.
Cost and utility estimations
Our model required cost and utility estimations for the
following unique states: ICU admission status (over-
treated, adherent, and under-treated), ward admission
status (over-treated, adherent, and under-treated), ward
clinically stable (over-treated, adherent, and under-
treated), discharge status, and death. Costs were adjusted
according the US consumer price index to 2013 US dol-
lars. Average daily hospital costs for a day in the ICU
were dynamically modeled, with mean daily costs ran-
ging from $5132 on ICU day one to $3825 for day eight
and thereafter (c.f. medical costs reported in Table 4 in
Dasta et al. [22], adjusted to 2013 US dollars). The daily
ICU costs were modeled with a gamma probability dis-
tribution with parameters κ and θ estimated from re-
ported standard deviations of cost data by Dasta et al.
[22] Mean daily ward costs for treatment of CAP were
estimated to be a static cost of $1060 per day (c.f.
Table 3, column ‘Simple Pneumonia’ in Kaplan et al.
[23]). Daily ward costs, like ICU costs, were modeled
with a gamma probability distribution with parameters
based on standard deviation estimates reported by
Kaplan et al. [23] The initial antibiotic regimen of each
cohort was retrieved from the CAPO database. Daily
antibiotic costs were estimated based on average whole-
sale prices (year 2013 value) of each antibiotic obtained
from the University of Louisville Hospital (Additional
file 1). The daily cost of each respective antibiotic regi-
men in our database was calculated and averaged for our
unique states described above. Admission status anti-
biotic regimens were intravenous, while patients in clin-
ical stability by definition were on oral medications.
Patients initially admitted to the ICU were assumed to
Fig. 1 Schematic of multi-state model. Multi-state Markov model of four possible states during hospitalization for community-acquired pneumo-
nia. For each possible transition the αij (t) represent the cause-specific transition hazard from state i to state j
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transfer to the ward upon reaching clinical stability. The
cost associated with each state was the sum of the hos-
pital charges for the location of treatment (ICU or ward)
and daily estimated antibiotic costs.
Utility estimations were obtained based on a survey
(Additional file 2) administered to an expert panel sur-
vey of six CAPO investigators. Each expert was polled
independently. While the executive director of CAPO
assisted in convening the expert panel, he was not in-
volved in the eliciting of utilities and was blinded to spe-
cific utility assessments. The demographics of the expert
panel survey were as follows: 50 % male; one Fellow,
four Assistant Professors, and one Professor; mean age
43.5; mean years of clinical practice experience was 18.
All respondents were currently practicing in the US.
Each survey respondent was asked to estimate the utility
associated with the following states in the context of a
standard gamble: ICU admission, ward admission, and
ward clinically stable. Utility was defined as an estimate
of relative quality of life on a scale of 0 to 1, with 0 being
death and 1 being at home. It was assumed that the util-
ity of each state would be independent of the antibiotic
adherence classification. The utility estimates were mod-
eled with a beta distribution, with shape parameters
based on the standard deviation of the expert panel sur-
vey results.
Probabilistic sensitivity analyses were performed for
the hospitals costs and utility estimates, since they were
modeled as probability distributions. Sensitivity analyses
of the fixed daily drug cost estimates were estimated in a
3-way analysis across ranges $1 to $100 in 20 intervals.
Strategy dominance was evaluated across willingness to
pay ranges from $0 to $1000, in 20 intervals. This range
was based on the generally used threshold of willingness
to pay of $100,000/QALY. Since our model cycles corre-
sponded to days, rather than years, a willingness to pay
range of 0 to $1000 per quality-adjusted life day corre-
sponds to 0 to $365,000 per QALY [24].
TreeAge Pro 2015 (Cambridge, MA) software was
used for all cost-effectiveness analyses.
Results
Model parameters
There were 1635 patients identified age ≥ 65 whose ini-
tial antibiotic regimens could be classified; 1438 of these
patients were admitted to the ward and 197 were admit-
ted to the ICU. Patient demographics for the ICU and
Ward patients according to antibiotic regimen are sum-
marized in Table 1, while the number and percentage of
patients on various antibiotic regimens is given in
Table 2.
The estimated daily transition probabilities for both
the parametric and non-parametric multi-state models
are given in Additional file 3 (ward) and Additional file 4
(ICU). The lines represent the probability of making a
transition from one state to another on sequential days.
The parametric model estimates were based on the co-
variate profile corresponding to the most frequent value
for each covariate. For the ward and ICU models these
were PSI risk class ≥4, absence of multilobar pneumonia,
pleural effusion, altered mental status, tachypnea, and
hypotension, antimicrobials not received within 8 h of
admission, no pneumococcal vaccination, and both
blood cultures obtained within 24 h of admission and
oxygen assessment done. For the ward model the para-
metric and non-parametric estimates agree fairly closely,
with the parametric estimates appearing smoother in the
over-treated case. For the ICU model again there is fairly
good agreement between the parametric and non-
parametric estimates, though the parametric model gen-
erally had higher estimated transition probabilities to
clinical stability/discharge status and lower transition
probabilities to in-hospital mortality. Note that for both
ICU and ward models once an absorbing state (dis-
charge and in-hospital death) is reached the probability
to remain in that state is one.
The daily transition probabilities from the parametric
model based on the given covariate profile were used to
build the Markov model for analysis. The proportions of
patients occupying the four unique states in the Markov
model over time are represented in Fig. 2. Daily cost and
utility estimates for each state are given in Table 3. Per
stage and cumulative cost estimates for both models are
presented in Fig. 3, demonstrating decreased daily and
cumulative costs for the adherent cohort relative to the
over- and under-treated cohorts in the ward model.
However, in the ICU model the over-treated cohort had
decreased costs compared to the adherent and under-
treated cohorts. Per stage and cumulative utility esti-
mates are presented in Fig. 4, demonstrating increased
utility in the adherent strategy in the ward model and
the over-treated strategy for the ICU model.
Base case analysis
The cost effectiveness analysis results for the ward
model are summarized in Table 4. The adherent strategy
was the dominant cost-effective decision in this set of
patients. Patients treated with an antibiotic regimen that
was adherent to the recommendations of the 2007
IDSA/ATS guidelines experienced lower costs and in-
creased utility compared to patients treated with an
over- or under-treatment regimen. On average, total
hospitalization costs were $1379 and $799 less in the ad-
herent group compared to the over- and under-treated
groups, respectively.
The cost effectiveness analysis results for the ICU
model are summarized in Table 5. The over-treatment
strategy was the dominant cost-effective decision in this
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Table 1 Summary of Demographic and Clinical Parameters
Adherent Ward
n = 877 ICU n = 98
Over-treated Ward
n = 167 ICU n = 28
Under-treated Ward
n = 394 ICU n = 71
p-value
Male Gender Ward n = 1438 544 (62.0 %) 101 (60.5 %) 217 (55.1 %) 0.064a
ICU n = 197 58 (59.2 %) 25 (89.3 %) 37 (52.1 %) 0.0026a
Risk Class Ward n = 1438 0.0002a
1 0 0 1 (0.3 %)
2 45 (5.1 %) 10 (6.0 %) 11 (2.8 %)
3 206 (23.5 %) 23 (13.8 %) 76 (19.3 %)
4 462 (52.7 %) 82 (49.1 %) 196 (49.8 %)
5 164 (18.7 %) 52 (31.1 %) 110 (27.9 %)
ICU n = 197 0.56b
1 0 0 0
2 0 1 (3.6 %) 0
3 13 (13.3 %) 2 (7.1 %) 8 (11.3 %)
4 43 (43.9 %) 12 (42.9 %) 28 (39.4 %))
5 42 (42.9 %) 13 (46.4 %) 35 (49.3 %)
Nursing Home Ward n = 1438 61 (7.0 %) 27 (16.2 %) 44 (11.2 %) 0.0002a
ICU n = 197 4 (4.1 %) 3 (10.7 %) 5 (7.0 %) 0.39b
Cancer Ward n = 1438 85 (9.7 %) 24 (14.4 %) 60 (15.2 %) 0.0096a
ICU n = 197 9 (9.2 %) 4 (14.3 %) 7 (9.9 %) 0.723a
CHF Ward n = 1438 231 (26.3 %) 43 (25.8 %) 104 (26.4 %) 0.99a
ICU n = 197 45 (45.9 %) 8 (28.6 %) 35 (49.3 %) 0.16a
Stroke Ward n = 1438 186 (21.2 %) 36 (21.6 %) 131 (33.3 %) <0.0001a
ICU n = 197 11 (11.2 %) 0 18 (25.4 %) 0.0023b
COPD Ward n = 1438 321 (36.6 %) 66 (39.5 %) 116 (29.4 %) 0.0198a
ICU n = 197 40 (40.8 %) 9 (32.1 % 25 (35.2 %) 0.62a
Diabetes Ward n = 1438 195 (22.2 %) 44 (26.4 %) 82 (20.8 %) 0.35a
ICU n = 197 27 (27.6 %) 7 (25.0 %) 7 (9.9 %) 0.0169a
Liver Disease Ward n = 1438 25 (2.9 %) 4 (2.4 %) 12 (3.1 %) 0.91a
ICU n = 197 3 (3.1 %) 2 (7.1 %) 0 0.72b
Renal Disease Ward n = 1438 121 (13.8 %) 27 (16.2 %) 57 (14.5 %) 0.72a
ICU n = 197 18 (18.4 %) 3 (10.7 %) 8 (11.3 %) 0.36a
Age Ward 79 79 80 0.065c
ICU 75 73 79 0.0097c
PSI Score Ward 104 116 109.5 <0.0001c
ICU 123.5 126.5 130 0.6133c
Antibiotic Timing Ward 5 4.5 4.5 0.081c
ICU 6 3.5 5 0.15c
Discharge probability (14 day)e Ward 0.77 0.62 0.68 <0.001d
ICU 0.48 0.61 0.40 0.12d
Clinical stability probability (7 day)e Ward 0.75 0.57 0.60 <0.001d
ICU 0.40 0.57 0.34 0.027d
In-hospital mortality (14 day)e Ward 0.06 0.14 0.13 <0.001d
ICU 0.14 0.18 0.26 0.04d
a Chi-square
b Fisher exact test
c Medians compared with Kruskal-Wallis test
d Gray’s test for differences between cumulative incidence curves
e Reported discharge, clinical stability, and in-hospital mortality probabilities are all unadjusted or marginal probabilities
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set of patients. Patients treated with an antibiotic regi-
men that was in excess of the recommendations of the
2007 IDSA/ATS guidelines experienced lower costs and
increased utility compared to patient treated with an ad-
herent or under-treatment regimen. On average, total
hospitalization costs were $13,854 and $3461 more in
the adherent group relative to the over- and under-
treated groups, respectively.
Sensitivity analyses
Sensitivity analyses are summarized in Tables 6 and 7.
The over-treatment strategy remained the dominant
strategy across all of the ranges in the sensitivity analyses
for drug cost estimates in the ICU model. In the ward
model, the adherent strategy was dominant across all
variations in ward oral drug costs, but partially dominant
across variations in ward intravenous drug costs.
We determined changes in the dominant strategy
proportion over a range of willingness to pay values in the
probabilistic sensitivity analysis. Since the model mea-
sured daily cost and utility estimates, a conversion factor
was used and we varied the willingness to pay across a
range from 0 to $1000 per quality-adjusted life day, corre-
sponding to 0 to $365,000 per QALY [24]. The over-
treatment strategy remained the dominant strategy in >
60 % of the iterations in the ICU model across all levels of
willingness to pay, while the adherent strategy remained
the dominant strategy in the Ward model (Fig. 5).
Differences in length of stay were the most important
determinants of cost in the models, particularly in the
ICU. The dominant strategy of over-treatment in the
ICU was associated with lower overall length of stay
(median = 11 days) compared to the adherent and
under-treatment strategy (median = 14 days for both).
ICU length of stay varied greatly for the three strategies:
over-treatment (median = 4 days), adherent (median =
12 days), and under-treatment (median = 8 days). Length of
stay did not vary quite as much in the ward model: adher-
ent (median = 8 days), over-treatment (median = 10 days),
and under-treatment (median = 9 days).
Discussion
The most important finding in this work is that adher-
ence to the IDSA/ATS guidelines regarding empiric anti-
biotic therapy for elderly patients hospitalized with CAP
was cost effective compared to non-adherence in non-
ICU patients, but was not the most cost effective strat-
egy in ICU patients. Elderly patients admitted to the
ICU with CAP who were treated with an antibiotic regi-
men in excess of the IDSA/ATS guidelines had lower
costs and increased quality of life compared to those
treated with an adherent regimen.
The cost effectiveness implications of adherence to
treatment guidelines has been evaluated in a limited
number of settings, finding that in general, adherence
to treatment guidelines is cost effective. Adherence
with guidelines for sarcoma treatment was cost effect-
ive in a recent study from two European regions [12].
Adherence to guidelines has also been shown to be
cost-effective in such diverse fields as intrauterine in-
semination and hepatitis B therapy [10, 11]. A study
from Japan has shown the adherence to guidelines for
gastric ulcer therapy is cost effective in that country
[9]. Consensus treatment and practice guidelines have
the potential to not only standardize care and dissem-
inate best practice measures throughout complex
healthcare systems, but also may offer cost effective
strategies that are of particular importance in the
current era of health care utilization reform.
Adherence to guidelines for the treatment of CAP has
been associated with improved outcomes. An analysis of
Table 2 Number and Proportion of Patients in Antibiotic Groups





Adherent 877 (61 %) 98 (50 %)
β-lactam +macrolide 500 (35 %) 71 (36 %)
β-lactam +macrolide + vancomycin 0 (0 %) 1 (<1 %)
Quinolone 374 (26 %) 13 (7 %)
Quinolone + vancomycin 2 (<1 %) 0 (0 %)
Quinolone + β-lactam 0 (0 %) 12 (6 %)
Quinolone + β-lactam + vancomycin 0 (0 %) 1 (<1 %)
Other 1 (<1 %) 0 (0 %)
Undertreated 394 (27 %) 71 (36 %)
β-lactam 301 (21 %) 42 (21 %)
β-lactam + othera 50 (3 %) 15 (8 %)
β-lactam (antipseudomonal) +
macrolide
19 (1 %) 8 (4 %)
Macrolide 15 (1 %) 1 (<1 %)
Other 9 (1 %) 5 (3 %)
Overtreated 167 (12 %) 28 (14 %)
β-lactam (antipseudomonal) +
macrolide
19 (1 %) 2 (1 %)
β-lactam +macrolide + quinolone
or other
49 (3 %) 17 (9 %)
Quinolone +macrolide 8 (1 %) 0 (0 %)
Quinolone + β-lactam +/- otherb 64 (4 %) 4 (2 %)
Quinolone + othera 24 (2 %) 3 (2 %)
Macrolide + otherc 2 (<1 %) 1 (<1 %)
Other 1 (<1 %) 1 (<1 %)
a other = other than a macrolide
b The +/- here indicates that another antibiotic (other than vancomycin) may
or may not have been prescribed
c other = other than a β-lactam
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the same CAPO data used in this study found adherence
to guidelines improved mortality, LOS, and time to clin-
ical stability in elderly patients hospitalized with CAP
[8]. However, the previous study did not separate pa-
tients on the basis of admission to the ICU or ward.
Nonadherence to guidelines was associated with in-
hospital mortality in studies of both community hospi-
tals and tertiary teaching hospitals [25, 26]. These find-
ings of improved outcomes in both hospitalized and
outpatient settings with adherence to antibiotic guide-
lines have been replicated [27–29]. Nonadherence rates
were higher in patients treated by non-pulmonary spe-
cialists in one study [30]. The cost implications of adher-
ence to guidelines in hospitalized patients with CAP
have not been studied as extensively. One study from
Europe evaluated the cost-effectiveness of adherence to
Spanish guidelines for the treatment of hospitalized CAP
in non-ICU patients of any age [13]. This study found
that adherence to the guidelines was the dominant cost-
effective strategy compared to non-adherence. To our
knowledge, this study is the first to evaluate the cost-
effectiveness of adherence to guidelines in an exclusively
elderly population with CAP in a multi-institutional set-
ting, stratified by admission to the ICU or ward. Add-
itionally, this study accounts for the stochastic nature of
a hospital stay by estimating conditional transition prob-
abilities directly from the data using the Aalen-Johansen
estimator. This is an improved method by which to esti-
mate cost and utility changes during a hospitalization
course, as one is able to estimate daily, conditional
changes in the probability of transitioning between states
rather than averaging the transition probabilities over
the course of an entire hospitalization, thus providing
more precise estimates of cost and utility changes.
While the finding that adherence to IDSA/ATS guide-
lines was the dominant strategy in ward (non-ICU) pa-
tients was expected and is consistent with a previous
report, it was surprising to find that over-treatment was
the dominant strategy in ICU patients [13]. A close ana-
lysis of the state occupation probabilities used to build
Fig. 2 State occupation probabilities of multi-state model. State occupation probabilities in the multi-state Markov model by antibiotic regimen,
stratified by admission status (ICU or ward). Each stage corresponds to a single hospital day. Scale for y-axis for in-hospital mortality (death) is
from 0.0 to 0.2 to better illustrate separation between the different antibiotic strategies
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the model suggests the likely explanation is the acceler-
ated time to clinical stability in this cohort of patients,
which under our assumptions led to a reduction in ICU
LOS for these patients. Daily ICU costs were the domin-
ant driver of total costs in this model. Drug costs, which
are a direct consequence of empiric antibiotic therapy
choice, are miniscule compared to the daily cost of a
stay in the ICU, which is measured in thousands of dol-
lars per day. Thus, any large cost benefit from an anti-
biotic choice in relationship with the IDSA/ATS
guidelines would likely be driven by a reduction in ICU
and overall LOS rather than a reduction in daily drug
costs. In the CAPO cohort, ICU LOS was shorter in pa-
tients who were treated with an over-treated antibiotic
regimen compared to an adherent strategy. By hospital
day 5, only 43 % of over-treated patients initially admit-
ted to the ICU remained there, while the percentage of
patients treated with an adherent regimen remaining in
the ICU was nearly twice that (71 %) (Fig. 2). This led to
dramatic reductions in daily and cumulative costs, and
subsequent improvements in utility for the over-treated
group. The marginal (unadjusted) 14-day mortality rate
was higher in the over-treated group (18 %) compared to
the adherent group (14 %) (Table 1), though differences
in adjusted mortality rates were smaller (4.1 % vs. 2.4 %,
respectively, Fig. 2). Overall, the lower costs associated
with quicker transfer from the ICU to the ward made
the over-adherent treatment strategy the most cost
effective.
From this analysis, one cannot draw a conclusion of
direct causation regarding the implementation of an
overly-broad antibiotic regimen and the reduction in
ICU LOS, although there certainly seems to be a
strong association between an over-treatment strategy
and a decreased ICU LOS that leads to reduced hos-
pital costs. One potential explanation is the possibility
that the patients in the over-treatment cohort were
over-triaged to the ICU compared to adherent and
under-treated patients and thus were more likely to
leave the ICU earlier, independent of initial empiric
antibiotic coverage. However, the initial demographics
of our ICU patients suggest that the three antibiotic
groups were relatively similar (Table 1). Pulmonary
severity indices were not significantly different across
the antibiotic groups, nor were the differences in co-
morbid conditions such as cancer, congestive heart
failure, COPD, renal, or liver disease. Though the
sample size for the ICU was small, over-treated pa-
tients did have a significantly higher probability to
reach clinical stability by day 7 (Table 1), and in par-
ticular patients that received both a macrolide and a
quinolone in addition to a β-lactam. Interestingly, an-
other recent study of hospitalized CAP patients from
three world regions found an elevated risk of mortal-
ity associated with ICU patients prescribed flouroqui-
nolones relative to macrolides [31]. However, this
study did not investigate whether the combination of
a flouroquinolone with a macrolide provided any add-
itional benefit, nor did it investigate time to clinical
stability or length of hospital stay. These findings sug-
gest that strategies to reduce ICU LOS may include
aggressive empiric antibiotic regimens that can be
Table 3 Cost and Utility Estimationsa
ICU Ward








Daily Hospital Cost ($)c 5132 (4767) – 3825 (2658) 1060 (1141)
Utilityd
Admission Status 0.3 (0.063) 0.53 (0.10)
Clinically Stable 0.82 (0.13) 0.82 (0.13)
Discharge 1 1
Dead 0 0
a Reported as mean (standard deviation)
b Daily intravenous and oral antibiotic costs were estimated based on 2013 US wholesale prices from University of Louisville Hospital (Additional file 1)
c Daily hospitalization costs were estimated from Dasta et al. [22] for ICU and Kaplan et al. [23] for ward
d Daily utility estimates were based on a questionnaire administered to a panel of six experts (Additional file 2)
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later tailored to more targeted therapy guided by clin-
ical response and microbial laboratory findings.
The findings in this study were robust over a wide
range of sensitivity analyses performed. Sensitivity ana-
lyses of model parameters in multi-state Markov models
are a critical component of the evaluation of model find-
ings, as the model predictions are only as good as the
parameters used to build the model. Antibiotic costs
were estimated from a single local institution (University
of Louisville Hospital), thus a valid criticism would be
the external validity of these cost estimates to other hos-
pitals. Sensitivity analyses found that the dominant strat-
egies were robust over a wide range of daily antibiotic
costs, thus suggesting that these findings have external
validity to other institutions. Utility estimates are also
quite subjective. We attempted to control for this using
an expert panel of CAPO investigators who are familiar
with the care of elderly patients with CAP. Modeling the
utility estimates as a probability helps to account for this
variability in the probabilistic sensitivity analysis. State
occupation probabilities were available for the entire
30 day hospital course for our study cohort. We limited
our model to an analysis of only the first 14 days, rea-
soning that hospitalizations beyond 14 days for CAP in
the elderly likely were the result of complex, confound-
ing factors and associated comorbidities that were un-
affected by the initial empiric antibiotic coverage.
Sensitivity analysis, however, did confirm the cost dom-
inant strategies remained the same for models ana-
lyzed > 14 days.
The results reported here are based on the adjusted
transition probability estimates based on the parametric
models. However, conclusions based on the non-
parametric estimates were similar, with adherence being
the dominant strategy for the ward and over-treated the
dominant strategy for the ICU. If the setting of the Mar-
kov model was extended to include post-discharge util-
ity, then the difference in unadjusted mortality between
the adherent and other antiobiotic groups might have a
greater impact on the cost-effectiveness analysis. The
Fig. 3 Daily and cumulative cost estimates. Per stage (daily) and cumulative cost estimates according to antibiotic strategies, stratified by ICU or
ward admission status
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most salient difference between the adjusted and un-
adjusted models was the reduced probability of mortality
and increased probability of discharge and reaching clin-
ical stability in the ICU for the adjusted model relative
to the unadjusted estimates (Additional file 5).
The findings in this study must be considered with
consideration of the shortcomings. Decision analysis
models are only as strong as the parameters used to
build them. While every effort was made to develop the
model with realistic parameters, limitations arise in
estimating transition probabilities, cost and utility esti-
mates, and perspective of the model. Baseline differences
in the clinical risk factors among the three groups, in-
cluding PSI score and age, clearly have an impact on es-
timates of in-hospital mortality and discharge rates.
While attempts were made to limit their effect on the
model using adjusted transition probability estimates,
differences in clinical pathways, practice, and resource
utilization among the participating institutions and their
effects on the clinical outcomes measured in this study
Table 4 Cost effectiveness results in the ward model of hospitalized community-acquired pneumonia in the elderly according to
antibiotic regimen. Increment cost, utility, and cost/utility ratio were estimated relative to adherent as the base comparator
Adherent Over-Treated Under-Treated
Cost ($) 10,156 (4665 – 17,585) 11,535 (5339 – 20,179) 10,954 (5159-19,190)
Incremental Cost ($) +1379 (−8418 – 11,448) +799 (−8875 – 10,940)
Utility 11.2 (8.9 – 12.5) 10.1 (7.2 – 12.1) 10.5 (7.9 – 12.1)
Incremental Utility −1.0 (−4.2−1.9) −0.7 (−3.6–2.0)
Estimates presented as means (2.5th-97.5th percentile). Costs are in 2013 US dollars
Fig. 4 Daily and cumulative utility estimates. Per stage (daily) and cumulative utility estimates according to antibiotic strategies, stratified by ICU
or ward admission status
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cannot be discerned. An additional limitation is the as-
sumption that patients transitioned out of the ICU once
they reached clinical stability. This may not necessarily
be the case, as patients may require longer stays due to
deterioration of other comorbidities or other reasons.
However, on average patients who reach clinical stability
sooner should also leave the ICU earlier, so the observed
differences between antibiotic treatment classes should
be relatively robust. Finally, the estimated transition
probabilities for over-treated patients in the ICU were
based on only 28 patients, and require independent val-
idation of the finding that this treatment regime was
most cost-effective for these patients in the hospital
setting.
A second limitation of the model is how patient utility
estimates were obtained. The sample size of expert opin-
ions (six) was limited and only from US institutions.
While the experts were independently polled and we
have no reason to believe there responses were subject
to bias, an alternative method for obtaining a consensus
(e.g., the Delphi method) might be preferable. Co-
morbidities were not factored into the utility estimates
both to simplify the data collection and because we felt
this was not directly related to CAP/CAP therapy. Fi-
nally, using expert opinions to model patient-centric
utilities is less desirable than patient-based estimates.
While expert judgments concerning utilities should be
used sparingly, it became pragmatically difficult to elicit
utilities from patients and a data source does not exist in
which the specific utilities we needed were present. A
superior approach would be to estimate utilities based
on appropriate patient questionnaires, perhaps as part of
a prospective study to include post-discharge outcomes.
While we did not have the resources to obtain such data
as part of this study, future research will definitely take
this into consideration.
Third, the CAPO data used in this study does not con-
tain cost data, and external references and data were
used to model both hospitalization and antibiotic regi-
men costs. While it may prima facie seem inconsistent
to model costs from two different sources, we elected to
use data from Dasta et al. [22] in addition to Kaplan et
al. [23] for two reasons. First, the data from Dasta et al.
suggests that ICU costs are not constant, rather they
change over time. Hence these data are uniquely appro-
priate for use in a Markov model, in which one can cap-
ture these differences and make more accurate
inferences about differences in costs based on how many
days are spent in the ICU. Second, the data from Kaplan
et al. only provides estimates of the total hospitalization








Adherent Never Dominant Dominant when Under-Treatment IV drugs > $25
Over-Treatment Dominant Never Dominant
Under-Treatment Never Dominant Dominant in circumstances when Under-Treatment IV drugs < $25 and Adherent IV Drugs > $70
Ward Oral Drugsa
Adherent Never Dominant Dominant
Over-Treatment Dominant Never Dominant
Under-Treatment Never Dominant Never Dominant
a 3-Way analysis across daily drug costs of $1 to $100 in 20 intervals
Table 5 Cost effectiveness results in the ICU model of hospitalized community-acquired pneumonia in the elderly according to anti-
biotic regimen. Increment cost, utility, and cost/utility ratio were estimated relative to adherent as the base comparator
Adherent Over-Treated Under-Treated
Cost ($) 44,765 (20,243 – 76,890) 30,912 (11,383 – 60,682) 41,305 (17,102 – 74,067)
Incremental Cost ($) −13,854 (−51,699 – 24,938) −3461 (−44,741 – 37,677)
Utility 7.3 (4.3 – 10.6) 9.6 (5.2 – 12.3) 7.5 (3.9 – 11.1)
Incremental Utility +2.3 (−3.3 – 6.8) +0.2 (−8.8 – 5.2)
Estimates presented as means (2.5th-97.5th percentile). Costs are in 2013 US dollars
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Fig. 5 Dominant strategy proportions by willingness to pay. The proportion of times a given antibiotic regimen is dominant according to
different willingness to pay thresholds, stratified by ICU or ward admission status




Adherent Never Dominant Dominant
Over-Treatment Dominant when daily ICU costs > $2675 Never Dominant
Under-Treatment Partially dominant when daily ICU costs < $2675 and daily ward costs > $835a Never Dominantb
Utility Estimates
Adherent Never Dominant Dominant
Over-Treatment Dominant Never Dominant
Under-Treatment Never Dominantc Never Dominantd
a Two-way analysis, $100 to $5000 in 20 intervals (ward) and $500 to $15,000 in 20 intervals (ICU)
b One-way analysis, $100 to $5000 in 20 intervals
c 3-way analysis, 0.1 to 0.9 in 10 intervals for utility estimates (ICU, clinically stable, and ward)
d Two-way analysis, 0.1 to 0.9 in 10 intervals for utility estimates (clinically stable and ward)
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costs for patients initially treated for CAP in the ICU.
Thus these estimates capture both costs in the ICU and
in the ward, and an average cost per day calculation
from the Kaplan data would be “contaminated” with
time spent on the ward. Hence it is a less fit estimate for
daily ICU costs compared to the Dasta et al. data. Lastly,
costs were estimated based on US institutional rates but
applied to international data. However, since the results
were consistent across sensitivity analyses for costs and
willingness to pay thresholds, we feel the conclusions
are relatively robust to any regional variation in costs.
Finally, the conclusions here are based on the short-term
utility and cost-effectiveness for CAP patients during their
hospital stay. Since we did not have direct data concerning
post-discharge mortality and quality of life for this cohort
of patients, we did not attempt to model long-term cost-
effectiveness. While we have no evidence to suggest that
post-hospitalization outcomes are different among the
treatment cohorts in this study, we acknowledge that it is a
limitation of the model that it incorporates only a fraction
of the life-expectancy for these patients. However, our
multi-state modeling approach is easily extendable to
prospectively collected data on patients discharged after
hospitalization due to CAP [32–35]. For example, one
could model the post-discharge outcomes as additional
states within the Markov model, tracking transitions
between occurrence of various co-morbidities, re-
hospitalizations, and mortality. The multi-state model can
also be coupled with causal inference approaches to assess
the effect of various interventions/treatment regimens on
outcomes of interest. For example, such models have been
fit in other disciplines to evaluate whether partial versus full
time sick leave and having a cooperation agreement is help-
ful in reducing sickness absence from work [36]. In a simi-
lar fashion, a multi-state model coupled with causal
inference approaches may form the basis of active, pro-
spective evaluation of antibiotic choices and the cost-
effectiveness of adherence to recommended guidelines.
Patient quality of life would then be ideally collected using
appropriate designed patient questionnaires. As a final
thought, such studies would also need to take into consid-
eration the effect of antibiotic regimen on antimicrobial
resistance. The societal costs of antibiotic over-treatment
pressures on the development of antimicrobial resistance
are hidden costs to the over-treatment strategy that must
be considered.
Conclusion
In conclusion, this study found the adherence to IDSA/
ATS guidelines in elderly patients hospitalized with CAP
was cost-effective for patients admitted to a non-ICU set-
ting. For patients admitted to the ICU, over-treatment rela-
tive to adherence to IDSA/ATS guidelines was associated
with decreased ICU and overall LOS; subsequent to these
LOS reductions, over-treatment was the most cost-effective
strategy in these particular patients. The prospective evalu-
ation of empiric antibiotic treatments in CAP and the
resulting cost implications of these choices remain to be
determined.
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